Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of BT01001 Ophthalmic Solution in Healthy Adult Volunteers
NCT07313722Phase 1Recruiting
- Sponsor
- Beyang Therapeutics
- Start
- Nov 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BT01001 (14 arms), sponsored by Beyang Therapeutics. Primary endpoints: Number of Participants With Adverse Events up to 14 days and Dose-Limiting Toxicity. Started Nov 2025; status: recruiting.
02
Drugs
BT01001
Beyond the preview
Go deeper on NCT07313722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07313722.